SCYNEXIS (LSE:0L49) - Stock Price, News & Analysis

0L49 Stock Overview

A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. More details

0L49 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 97.3% below our estimate of its fair value

Earnings are forecast to grow 48.7% per year

Analysts in good agreement that stock price will rise by 437.6%

Risk Analysis

Volatile share price over the past 3 months compared to the UK market

Does not have a meaningful market cap ($47M)

SCYNEXIS, Inc. Competitors

Shield Therapeutics

AIM:STX

UK£22.7m

Redx Pharma

AIM:REDX

UK£58.3m

ECO Animal Health Group

AIM:EAH

UK£44.4m

Kanabo Group

LSE:KNB

UK£6.0m

Price History & Performance

Summary of all time highs, changes and price drops for SCYNEXIS
Historical stock prices
Current Share Price	US$1.27
52 Week High	US$3.07
52 Week Low	US$1.17
Beta	1.5
11 Month Change	-10.25%
3 Month Change	-18.94%
1 Year Change	-21.12%
33 Year Change	-81.90%
5 Year Change	n/a
Change since IPO	-93.32%

Recent updates

Shareholder Returns

	0L49	GB Pharmaceuticals	GB Market
7D	9.0%	4.2%	1.7%
1Y	-21.1%	3.0%	8.4%

Return vs Industry: 0L49 underperformed the UK Pharmaceuticals industry which returned 2.5% over the past year.

Return vs Market: 0L49 underperformed the UK Market which returned 8.8% over the past year.

Price Volatility

Is 0L49's price volatile compared to industry and market?
0L49 volatility
0L49 Average Weekly Movement	9.3%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0L49's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0L49's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
1999	29	David Angulo	www.scynexis.com

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
0L49 fundamental statistics
Market cap	US$47.06m
Earnings (TTM)	-US$36.44m
Revenue (TTM)	US$8.57m

5.5x

P/S Ratio

-1.3x

P/E Ratio

Is 0L49 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0L49 income statement (TTM)
Revenue	US$8.57m
Cost of Revenue	US$14.68m
Gross Profit	-US$6.12m
Other Expenses	US$30.32m
Earnings	-US$36.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.96
Gross Margin	-71.42%
Net Profit Margin	-425.41%
Debt/Equity Ratio	22.6%

How did 0L49 perform over the long term?

See historical performance and comparison

0L49 Stock Overview

Rewards

Risk Analysis

SCYNEXIS, Inc. Competitors

AIM:STX

UK£22.7m

AIM:REDX

UK£58.3m

AIM:EAH

UK£44.4m

LSE:KNB

UK£6.0m

Price History & Performance

Recent News & Updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

New major risk - Share price stability

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment deteriorates as stock falls 33%

Investor sentiment deteriorates as stock falls 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Insufficient new directors

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

Insufficient new directors

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Insufficient new directors

Insufficient new directors

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Shareholder Returns

Price Volatility

About the Company